NF-κB as potential target in the treatment of melanoma

Gabriele Madonna, Claudio D. Ullman, Giusy Gentilcore, Giuseppe Palmieri, Paolo A. Ascierto

Research output: Contribution to journalArticle


The RAS/MAP kinase pathway has attracted attention because activating mutations of the BRAF serine/threonine kinase was described in over 50% of melanomas. Very recently, selective and potent BRAF inhibitors have been developed. Several other signal transduction pathways have been found to be constitutively active or mutated in other subsets of melanoma tumors that are potentially targetable with new agents. Among these, NFκB is another pathway that melanoma tumors use to achieve survival, proliferation and resistance to apoptosis. Inhibition of NF-κB activation appears to be a very promising option for anti-cancer therapies.

Original languageEnglish
Article number53
JournalJournal of Translational Medicine
Issue number1
Publication statusPublished - Mar 20 2012


  • Bortezomib
  • Curcumin
  • Melanoma
  • NBD peptide
  • Nf-κb

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'NF-κB as potential target in the treatment of melanoma'. Together they form a unique fingerprint.

  • Cite this